Evidence map›Paper›PMID 29541394›Full record

ArticleOncotarget2018

Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden.

Fernando Revert, Francisco Revert-Ros, Raül Blasco, Aida Artigot, Ernesto López-Pascual, Roberto Gozalbo-Rovira, Ignacio Ventura, Elain Gutiérrez-Carbonell, Nuria Roda, Daniel Ruíz-Sanchis and 7 more

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04626089 (Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04626089 phase2withdrawnstarted 2021, after this paper: background citation

Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.

Ran2021Enrolled0Registered outcomes12Posted comparisons0ConditionsMetabolic Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Type 2 DiabetesArmsMetformin glycinate, Placebo Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Fernando RevertFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Francisco Revert-RosFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Raül BlascoFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Aida ArtigotFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Ernesto López-PascualFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Roberto Gozalbo-RoviraFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Ignacio VenturaFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Elain Gutiérrez-CarbonellFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Nuria RodaDepartament de Bioquímica i Biologia Molecular, Universitat de València, Burjassot 46100, Spain.
Daniel Ruíz-SanchisFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Jerónimo FortezaInstituto Valenciano de Patología of Universidad Católica de Valencia, Centro de Investigación Príncipe Felipe, Valencia 46012, Spain.
Javier AlcácerAnatomía Patológica, Hospital Quirónsalud de Valencia, Valencia 46010, Spain.
Alejandra Pérez-SastreFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Ana DíazUnitat Central d'investigació en Medicina, Facultat de Medicina i Odontologia, Universitat de València, Valencia 46010, Spain.
Enrique Pérez-PayáDepartament de Bioquímica i Biologia Molecular, Universitat de València, Burjassot 46100, Spain.
Juan F Sanz-CerveraDepartament de Química Orgànica, Universitat de València, Burjassot 46100, Spain.
Juan SausFibroStatin, Parc Científic Universitat de València, Paterna 46980, Spain.
Parc Científic de la Universitat de València · ESUniversitat de València · ESCentro de Investigacion Principe Felipe · ESHospital Quirónsalud Barcelona · ESValencia Catholic University Saint Vincent Martyr · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Goodpasture antigen-binding protein (GPBP) is an exportable

Indexed as

collagen IVdrug-resistant cancerEMTGPBPtumor microenvironment

Identifiers

PMID29541394
PMCPMC5834258
OpenAlexW2789703328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.